Actinogen Medical (ASX:ACW) said it completed the final patient visit in a phase 2b/3 clinical trial of its Xanamem oral therapy for Alzheimer's disease, according to a Wednesday filing with the Australian bourse.
Top-line results for the trial remain on track for November, the company said.
The company's shares jumped 5% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments